Results 41 to 50 of about 939,403 (293)

Platelet-tumor-endothelium interaction under flow.

open access: yes, 2017
a) Photomicrographs show platelet and M21 aggregate formation under flow (1000/s). Co-perfusion of platelets and M21 cells induced formation of aggregates which did not firmly adhere and are therefore only partly focused (middle picture; arrows indicate ...
Georg Enders (187983)   +13 more
core   +1 more source

Smaller is better: nanobodies meet NMR

open access: yesFEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Platelet alloimmunization in transfusion-dependent thalassemia patients from Southern China (2014-2023)

open access: yesFrontiers in Immunology
Patients with transfusion-dependent thalassemia (TDT) are at high risk of alloimmunization. While previous research is predominantly focused on red blood cell alloimmunization, the potential risks of platelet alloimmunization are frequently ...
Yuchen Huang   +10 more
doaj   +1 more source

Platelet transfusion refractoriness in patients with acute myeloid leukemia: The role of anti-platelet antibodies [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. Platelet transfusion refractoriness represents a common issue in the treatment course of acute myeloid leukemia (AML) patients who require chronic transfusion support.
Đunić Irena   +3 more
doaj   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

open access: yesMolecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang   +9 more
wiley   +1 more source

Laboratory analyses for evaluation of platelet disorders and platelet concentrates [PDF]

open access: yes, 2006
High quality of platelet analytics requires specialized knowledge and skills. It was applied to analyze platelet activation and aggregation responses in a prospective controlled study of patients with Finnish type of amyloidosis.
Javela, Kaija
core  

Anti-platelet therapy: ADP receptor antagonists. [PDF]

open access: yes, 2011
The P2Y(12) receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet involvement in both haemostasis and thrombosis.
Heptinstall, S   +3 more
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Down-regulation of platelet surface CD47 expression in Escherichia coli O157:H7 infection-induced thrombocytopenia. [PDF]

open access: yesPLoS ONE, 2009
BACKGROUND: Platelet depletion is a key feature of hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) infection.
Ya-Lan Guo   +4 more
doaj   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

open access: yesFEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy